SS31 vs Mots-C | Controversy Heats Up Over New Supplement Protocols
A growing debate surrounds the order of taking SS31 before Mots-C for mitochondrial health. New insights from community conversations suggest users are pushing for tailored approaches, with emphasis on individual health conditions and experiences.
Opinions on Supplement Timing
Emerging discussions challenge the traditional view that SS31 must precede Mots-C. Some users firmly state there’s no solid clinical backing for this sequence, suggesting that protocols are often based on theoretical reasoning rather than clinical trials.
"You don't need to do SS31 before Mots. It's just theoretical reasoning," one commenter asserted, reflecting the skepticism about the conventional sequence.
Individual Protocols Take Center Stage
Many people advocate for more personalized supplementation strategies. One user mentioned a routine of investing in 2 vials of Mots-C followed by 1 vial of SS31, demonstrating an adaptable approach that aligns with individual needs.
Interestingly, a participant highlighted their struggles with fatigue while on SS31, but they viewed it as a sign of effective mitochondrial repair work. They plan to switch to Mots-C once their energy stabilizes, underscoring the personal journey many users face while trying to optimize health outcomes.
Age and Mitochondrial Damage Reassessment
As the conversation evolves, age and severity of mitochondrial damage are increasingly noted as pivotal factors. Individuals over 40, particularly, emphasize prioritizing SS31 for its repair potential, yet notable exceptions exist. One participant claimed that mild mitochondrial decline might not necessitate starting with SS31, hinting at a shift in how therapies are approached based on personal severity.
Volatile perspectives emerge as people weigh in: "If you're over 40, starting with SS31 makes sense," evidencing the mixed sentiment still prevalent throughout the community.
Community Insights
The community remains divided, with some users optimistic about SS31 leading the way while others endorse a more versatile method of combining both treatments from the get-go. Key sentiments revealed include:
🔄 "The new protocol could change everything for those with moderate issues."
⚡ "Responses vary widely; finding what works for you is critical."
⚠️ "You may as well flip a coin with all the different protocols shared."
With these differing narratives, it’s evident that individual experiences will continue to shape the direction of recommendations in mitochondrial health supplementation. Can a consensus emerge amidst such divergence?